Ginger effect on chemotherapy-induced neuropathy

Assessment of ginger and corn starch effect on chemotherapy-induced neuropathy in patients with ovarian and lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013121415780N1

Enrollment

Registered

2014-03-15

Start date

2014-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: ovarian cancer. Condition 2: lung cancer. Malignant neoplasm of ovary Malignant neoplasm of bronchus and lung

Interventions

Intervention 1: Supplemented group: 2 g oral ginger daily( 2 one-gram tablets of ginger)for 18 weeks. Intervention 2: Placebo group: 2 g oral corn starch daily( 2 one-gram tablets of corn starch)for 1

Prevention

Supplemented group: 2 g oral ginger daily( 2 one-gram tablets of ginger)for 18 weeks

Placebo group: 2 g oral corn starch daily( 2 one-gram tablets of corn starch)for 18 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:suffering from ovarian cancer; non-small cell lung cancer; willingness to corporate. Exclusion Criteria:age more than 70 years; suffering from diabetes; AIDS;hyperthyroidism; primary neurological diseases; other kinds of malignancies; history of chemotherapy; consumption of vitamin; mineral or fish oil supplementation at list 3 months before the enrollment; Ginger sensitivity

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Incidence of chemotherapy-induced peripheral neuropathy. Timepoint: before the onset of chemotherapy and after 18 weeks, at the end of the treatment period. Method of measurement: rTNS Score, Nerve Conduction Studiy.;Severity of chemotherapy-induced peripheral neuropathy. Timepoint: before the onset of chemotherapy and after 18 weeks, at the end of the treatment period. Method of measurement: rTNS Score, Nerve Conduction Studiy.	—

Measure

Time frame

Incidence of chemotherapy-induced peripheral neuropathy. Timepoint: before the onset of chemotherapy and after 18 weeks, at the end of the treatment period. Method of measurement: rTNS Score, Nerve Conduction Studiy.;Severity of chemotherapy-induced peripheral neuropathy. Timepoint: before the onset of chemotherapy and after 18 weeks, at the end of the treatment period. Method of measurement: rTNS Score, Nerve Conduction Studiy.

—

Secondary

Measure	Time frame
Serum levels of pro-inflammatory cytokines. Timepoint: before the onset of chemotherapy and after 18 weeks at the end of treatment. Method of measurement: ELISA.;Total Antioxidant Status (TAS). Timepoint: before the onset of chemotherapy and after 18 weeks at the end of treatment. Method of measurement: Spectrophotometry.;Serum level of MDA. Timepoint: before the onset of chemotherapy and after 18 weeks at the end of treatment. Method of measurement: Spectrophotometry.;Activity of SOD & GPX enzymes in RBC. Timepoint: before the onset of chemotherapy and after 18 weeks at the end of treatment. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Serum levels of pro-inflammatory cytokines. Timepoint: before the onset of chemotherapy and after 18 weeks at the end of treatment. Method of measurement: ELISA.;Total Antioxidant Status (TAS). Timepoint: before the onset of chemotherapy and after 18 weeks at the end of treatment. Method of measurement: Spectrophotometry.;Serum level of MDA. Timepoint: before the onset of chemotherapy and after 18 weeks at the end of treatment. Method of measurement: Spectrophotometry.;Activity of SOD & GPX enzymes in RBC. Timepoint: before the onset of chemotherapy and after 18 weeks at the end of treatment. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZohreh Ghoreishi

Nutrition Research Center, Tabriz University of Medical Sciences

ghoreishiz@tbzmed.ac.irzohreh_ghoreishy@yahoo.com+98 41 1335 2295

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026